Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cyclerion Therapeutics stock | $3.22

Own Cyclerion Therapeutics stock in just a few minutes.

Fact checked

Cyclerion Therapeutics, Inc is a biotechnology business based in the US. Cyclerion Therapeutics shares (CYCN) are listed on the NASDAQ and all prices are listed in US Dollars. Cyclerion Therapeutics employs 94 staff and has a trailing 12-month revenue of around USD$3.6 million.

How to buy shares in Cyclerion Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Cyclerion Therapeutics. Find the stock by name or ticker symbol: CYCN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cyclerion Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.22, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Cyclerion Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Cyclerion Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Cyclerion Therapeutics share price

Use our graph to track the performance of CYCN stocks over time.

Cyclerion Therapeutics shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$3.22
52-week rangeUSD$2.0769 - USD$8.96
50-day moving average USD$3.0202
200-day moving average USD$4.7036
Wall St. target priceUSD$4
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.736

Buy Cyclerion Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cyclerion Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cyclerion Therapeutics price performance over time

Historical closes compared with the close of $3.22 from 2020-12-18

1 week (2021-01-08) -1.23%
1 month (2020-12-16) 2.22%
3 months (2020-10-15) 8.42%
6 months (2020-07-15) -35.21%
1 year (2020-01-15) -4.73%
2 years (2019-01-12) N/A
3 years (2018-01-12) N/A
5 years (2016-01-12) N/A

Cyclerion Therapeutics financials

Revenue TTM USD$3.6 million
Gross profit TTM USD$4.5 million
Return on assets TTM -33.46%
Return on equity TTM -87%
Profit margin 0%
Book value $2.219
Market capitalisation USD$106 million

TTM: trailing 12 months

Shorting Cyclerion Therapeutics shares

There are currently 592,674 Cyclerion Therapeutics shares held short by investors – that's known as Cyclerion Therapeutics's "short interest". This figure is 3.6% down from 614,703 last month.

There are a few different ways that this level of interest in shorting Cyclerion Therapeutics shares can be evaluated.

Cyclerion Therapeutics's "short interest ratio" (SIR)

Cyclerion Therapeutics's "short interest ratio" (SIR) is the quantity of Cyclerion Therapeutics shares currently shorted divided by the average quantity of Cyclerion Therapeutics shares traded daily (recently around 392499.33774834). Cyclerion Therapeutics's SIR currently stands at 1.51. In other words for every 100,000 Cyclerion Therapeutics shares traded daily on the market, roughly 1510 shares are currently held short.

However Cyclerion Therapeutics's short interest can also be evaluated against the total number of Cyclerion Therapeutics shares, or, against the total number of tradable Cyclerion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyclerion Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cyclerion Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0191% of the tradable shares (for every 100,000 tradable Cyclerion Therapeutics shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyclerion Therapeutics.

Find out more about how you can short Cyclerion Therapeutics stock.

Cyclerion Therapeutics share dividends

We're not expecting Cyclerion Therapeutics to pay a dividend over the next 12 months.

Cyclerion Therapeutics overview

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site